Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of alendronate [alendronic acid] and raloxifene on bone mineral density in postmenopausal women with osteoporosis

Trial Profile

A randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of alendronate [alendronic acid] and raloxifene on bone mineral density in postmenopausal women with osteoporosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alendronic acid (Primary) ; Raloxifene
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 01 Oct 2008 Planned number of patients changed from 400 to actual number 400 as reported by ClinicalTrials.gov
  • 01 Oct 2008 Actual end date added as 1 Jan 2003 as reported by ClinicalTrials.gov.
  • 13 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top